AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 211 min read$ILMN

Meister Keith A. sold $145.6M of ILMN (indirect holdings)

Meister Keith A. sold 679,574 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $214.19 ($202.37–$220.13, $145.56M total) across 28 trades over 2026-08-19 to 2026-08-21.

Original reporting
SEC EDGAR · Meister Keith A.
Published Aug 21, 2026, 11:42 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 22, 2026, 12:06 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ILMN
Bearish
high confidence
Mentioned
$ILMN
Relevance
8/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNBearishHigh
01

Why it matters

The sizable divestiture by a director may trigger short‑term sell pressure and influence analyst sentiment.

02

Market read

Large insider sale provides fresh material for traders; likely short‑term downside bias.

03

What to watch

Potential tax planning or diversification motives not disclosed.

Relevance 8/10Novelty 9/10Timing: post‑market Aug 21

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$ILMNBearishHigh confidence
Context

Director Meister Keith A. sold $145.6M (679,574 shares) of Illumina in open‑market trades.

Expected impact

Short‑term downward pressure on ILMN price.

Evidence & confidence

Sale size exceeds $100M and represents a significant portion of holdings, likely signaling reduced confidence.

Market effects

Sector

May raise concerns for the genomics/diagnostics sector about insider confidence.

Regional

Limited to US biotech market; no broader regional effect.

Global

Minimal global impact beyond Illumina investors.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • company
    Illumina, Inc.

    US‑listed genomics and diagnostics firm (NASDAQ: ILMN).

  • person
    Meister Keith A.

    Director of Illumina.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ILMN insider trading history →

Related articles

AUG 17
$ILMNMed

Illumina Raises $300M in New 2029 Notes to Repay Near

Illumina (ILMN) said it completed a $300 million public offering of new senior notes due Sept. 19, 2029, carrying a 4.950% coupon paid semiannually. Net proceeds plus cash will repay its 4.650% notes due Sept. 9, 2026, with $500 million outstanding as of July 28, 2026. The refinancing may raise annual interest expense.

minichart.com.sg3 min
AUG 4
$ILMNHighAI 9/10

Illumina (ILMN) Q2 2026 Earnings Call Transcript

Illumina (ILMN) reported Q2 2026 revenue of $1.16B, up 9.5% YoY, and non-GAAP EPS of $1.31. Clinical consumables and NovaSeq X placements drove results. Gross margin was 68.2%. Full-year 2026 guidance was raised to $4.60B-$4.64B revenue and $5.30-$5.40 EPS. Cash was $1.17B vs $1.99B debt.

fool.com6 min
JUL 31
$ILMNHighAI 9/10

Illumina (ILMN) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Head of Investor Relations - Conor McNamara Chief Executive Officer - Jacob Thaysen Chief Financial Officer - Ankur Dhingra TAKEAWAYS Total Revenue -- $1.16 billion, representing a 9.5% increase year over year driven by clinical market demand and the NovaSeq X expansion. Rest of World Organic Revenue -- Increased 8.1% year over year, exceeding the high end of management's previous guidance.

fool.com6 min
JUL 30
$ILMNMedAI 8/10

Illumina (NASDAQ:ILMN) Surprises With Q2 CY2026 Sales, Full

Genomics company Illumina (NASDAQ: ILMN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.62 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.31 per share was 6.8% above analysts’ consensus estimates. Is now the time to buy Illumina? Find out by accessing our full research report, it’s free.

financialcontent.com6 min
JUL 30
$ILMNHigh

ILLUMINA, INC. (ILMN): Results of Operations and Financial Condition

ILLUMINA, INC. (ILMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q226earningsrelease.htm EX-99.1 Document Investors: Conor McNamara +1.858.291.6421 ir@illumina.com Media: Christine Douglass pr@illumina.com Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026 San Diego, July 30, 2026 /PRNewswire/ -- Illumina, Inc.

SEC EDGAR 8-K3 min
Meister Keith A. sold $145.6M of ILMN (indirect holdings) — alphai